Cathie T Chung

Summary

Affiliation: Stanford University
Country: USA

Publications

  1. ncbi request reprint The role of aromatase inhibitors in early breast cancer
    Cathie T Chung
    Division of Oncology, Stanford University, 300 Pasteur Drive, H0274, Stanford, CA 94305, USA
    Curr Treat Options Oncol 4:133-40. 2003
  2. ncbi request reprint Adjuvant aromatase inhibitors following tamoxifen for early-stage breast cancer in postmenopausal women: what do we really know?
    Cathie T Chung
    Division of Oncology, Stanford University, CA 94305, USA
    Clin Breast Cancer 5:S18-23. 2004
  3. doi request reprint Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women
    Robert W Carlson
    Stanford Cancer Center, Stanford University, Stanford, CA 94305, USA
    J Clin Oncol 28:3917-21. 2010
  4. ncbi request reprint Goals and objectives in the management of metastatic breast cancer
    Cathie T Chung
    Division of Oncology, Stanford University, Stanford, California, USA
    Oncologist 8:514-20. 2003
  5. ncbi request reprint Breast cancer-specific mortality after invasive local recurrence in patients with ductal carcinoma-in-situ of the breast
    Laura A Lee
    Keck School of Medicine, University of Southern California, Los Angeles, CA 90033 0800, USA
    Am J Surg 192:416-9. 2006

Collaborators

Detail Information

Publications5

  1. ncbi request reprint The role of aromatase inhibitors in early breast cancer
    Cathie T Chung
    Division of Oncology, Stanford University, 300 Pasteur Drive, H0274, Stanford, CA 94305, USA
    Curr Treat Options Oncol 4:133-40. 2003
    ..New AIs may challenge the position of tamoxifen as the gold standard for the treatment of early stage breast cancer in postmenopausal women...
  2. ncbi request reprint Adjuvant aromatase inhibitors following tamoxifen for early-stage breast cancer in postmenopausal women: what do we really know?
    Cathie T Chung
    Division of Oncology, Stanford University, CA 94305, USA
    Clin Breast Cancer 5:S18-23. 2004
    ..There is now substantial medical evidence supporting the use of AIs in postmenopausal women with early-stage, HR-positive breast cancer...
  3. doi request reprint Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women
    Robert W Carlson
    Stanford Cancer Center, Stanford University, Stanford, CA 94305, USA
    J Clin Oncol 28:3917-21. 2010
    ....
  4. ncbi request reprint Goals and objectives in the management of metastatic breast cancer
    Cathie T Chung
    Division of Oncology, Stanford University, Stanford, California, USA
    Oncologist 8:514-20. 2003
    ..Both physician and patient perspectives are important in establishing the objectives of treatment, and this process is optimally an interactive and ongoing process throughout the course of disease...
  5. ncbi request reprint Breast cancer-specific mortality after invasive local recurrence in patients with ductal carcinoma-in-situ of the breast
    Laura A Lee
    Keck School of Medicine, University of Southern California, Los Angeles, CA 90033 0800, USA
    Am J Surg 192:416-9. 2006
    ..Our objective was to detail the outcomes of local invasive recurrence, distant recurrence, and breast cancer mortality in patients previously treated for DCIS...